Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 2,205 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Active, not recruiting Phase 3 Interventional Results available

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

NCT03375320
View directory record Official record
Conditions
Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
432
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 289 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Minocycline to Reduce Pain After Carpal Tunnel Release

NCT02051296
View directory record Official record
Conditions
Chronic Pain, Post-operative Pain
Interventions
Minocycline, placebo
Drug
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of a TAP Block Given During Laparoscopic Colorectal Surgery to Help Control Pain

NCT01731782
View directory record Official record
Conditions
Colorectal Disease
Interventions
bupivacaine, normal saline placebo (for bupivacaine)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 7, 2026, 5:10 PM EDT
Not listed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

NCT02130882
View directory record Official record
Conditions
Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions
benralizumab, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Not applicable Interventional Results available

Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes

NCT01580813
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Acipimox, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 7, 2026, 5:10 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)

NCT05275686
View directory record Official record
Conditions
Eustachian Tube Dysfunction
Interventions
Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray, Placebo Nasal Spray
Drug · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Sacramento, California • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 7, 2026, 5:10 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

NCT06241573
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Phase 4 Interventional Results available

Effect of L-dopa In Subacute Back Pain Population

NCT01951105
View directory record Official record
Conditions
Sub-acute Back Pain
Interventions
Naproxen, Carbidopa/Levodopa, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

NCT01836523
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
70
States / cities
Little Rock, Arkansas • Concord, California • Encino, California + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

NCT00464269
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam 2.5 mg, Brivaracetam 10 mg, Brivaracetam 25 mg
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Not applicable Interventional

L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD

NCT07189442
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD)
Interventions
L-theanine and paraxanthine, Placebo
Dietary Supplement
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02107196
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
65
States / cities
Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Not applicable Interventional Results available

Lidocaine Analgesia For Removal Of Wound Vac Dressings

NCT01126359
View directory record Official record
Conditions
Pain
Interventions
Lidocaine, Placebo-Saline
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury

NCT00755079
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
extended release beta-2 adrenergic agonist, placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

NCT02943460
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Cilofexor, Placebo to match cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
16
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis

NCT02049203
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Ataciguat, Placebo
Drug
Lead sponsor
Jordan D. Miller, Ph.D.
Other
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Phase 4 Interventional Results available

Predictors of Antidepressant Response

NCT02178696
View directory record Official record
Conditions
Depression
Interventions
Placebo, identified as placebo to participants, Celexa or other antidepressant as clinically indicated, Placebo, identifed to participants as "Active medication"
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05067127
View directory record Official record
Conditions
C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Interventions
Pegcetacoplan, Placebo
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

NCT03347708
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
IDCT, Saline Solution, Sodium Hyaluronate
Biological · Drug
Lead sponsor
DiscGenics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 7, 2026, 5:10 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Measuring Acute Drug Demand in Humans

NCT05829655
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Dependence
Interventions
Drug A (Blinded Drug), Drug B (Blinded Drug), Drug C (Blinded Drug), Drug D (Blinded Drug), Suvorexant (20mg/day), Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 7, 2026, 5:10 PM EDT
Not listed Phase 2 Interventional

Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders

NCT06503978
View directory record Official record
Conditions
Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
Interventions
MTP-101P, Vancomycin, Miralax, Antacid, Placebo MTP-101P, Placebo Vancomycin
Combination Product
Lead sponsor
Gut-Brain-Axis Therapeutics Inc.
Other
Eligibility
4 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Higher Dose Intradermal H5 Vaccine

NCT00439335
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A Vaccine A/H5N1, Placebo (IM), Placebo (ID)
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 7, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Interleukin-1 Blockade in HF With Preserved EF

NCT02173548
View directory record Official record
Conditions
Heart Failure With Normal Ejection Fraction
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 7, 2026, 5:10 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo

NCT05949008
View directory record Official record
Conditions
NIDDM, Obesity
Interventions
Metformin Extended Release (ER) Oral Tablet, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 7, 2026, 5:10 PM EDT